A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
Public ClinicalTrials.gov record NCT01085084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams \[mg\] and 1 mg) in participants with active lupus arthritis. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.
Study identification
- NCT ID
- NCT01085084
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2010 (Actual)
- Primary completion
- Nov 12, 2012 (Actual)
- Completion
- Nov 12, 2012 (Actual)
- Last update posted
- Jul 7, 2022
2010 – 2012
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1363 | Birmingham | Alabama | 35216 | — |
| Teva Investigational Site 1368 | Los Angeles | California | 90048 | — |
| Teva Investigational Site 1359 | Los Angeles | California | 90095-7077 | — |
| Teva Investigational Site 1352 | San Francisco | California | 94143-0792 | — |
| Teva Investigational Site 1365 | San Leandro | California | 94578 | — |
| Teva Investigational Site 1357 | Stanford | California | 94305 | — |
| Teva Investigational Site 1367 | Chicago | Illinois | 60637 | — |
| Teva Investigational Site 1370 | Baltimore | Maryland | 21205 | — |
| Teva Investigational Site 1362 | Cumberland | Maryland | 21502 | — |
| Teva Investigational Site 1360 | Hagerstown | Maryland | 21740 | — |
| Teva Investigational Site 1353 | Manhasset | New York | 11030 | — |
| Teva Investigational Site 1355 | New York | New York | 10016 | — |
| Teva Investigational Site 1369 | The Bronx | New York | 10467 | — |
| Teva Investigational Site 1356 | Charlotte | North Carolina | 28210 | — |
| Teva Investigational Site 1354 | Columbus | Ohio | 43210 | — |
| Teva Investigational Site 1366 | Charleston | South Carolina | 29425 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01085084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01085084 live on ClinicalTrials.gov.